304 related articles for article (PubMed ID: 31897532)
1. Impact of genetic variants of selected cytochrome P450 isoenzymes on pharmacokinetics and pharmacodynamics of clopidogrel in patients co-treated with atorvastatin or rosuvastatin.
Karaźniewicz-Łada M; Krzyżańska D; Danielak D; Rzeźniczak J; Główka F; Słomczyński M; Burchardt P
Eur J Clin Pharmacol; 2020 Mar; 76(3):419-430. PubMed ID: 31897532
[TBL] [Abstract][Full Text] [Related]
2. Influence of statin treatment on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites in patients after coronary angiography/angioplasty.
Karaźniewicz-Łada M; Rzeźniczak J; Główka F; Gumienna A; Dolatowski F; Słomczyński M; Burchardt P
Biomed Pharmacother; 2019 Aug; 116():108991. PubMed ID: 31136946
[TBL] [Abstract][Full Text] [Related]
3. Relationship between statin type and responsiveness to clopidogrel in patients treated with percutaneous coronary intervention: a subgroup analysis of the CILON-T trial.
Suh JW; Cha MJ; Lee SP; Chae IH; Bae JH; Kwon TG; Bae JW; Cho MC; Rha SW; Kim HS
J Atheroscler Thromb; 2014; 21(2):140-50. PubMed ID: 24140730
[TBL] [Abstract][Full Text] [Related]
4. Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study.
Park Y; Jeong YH; Tantry US; Ahn JH; Kwon TJ; Park JR; Hwang SJ; Gho EH; Bliden KP; Kwak CH; Hwang JY; Kim S; Gurbel PA
Eur Heart J; 2012 Sep; 33(17):2151-62. PubMed ID: 22507978
[TBL] [Abstract][Full Text] [Related]
5. Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel.
Danielak D; Karaźniewicz-Łada M; Wiśniewska K; Bergus P; Burchardt P; Komosa A; Główka F
Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):99-107. PubMed ID: 26891871
[TBL] [Abstract][Full Text] [Related]
6. Impact of common ABCB1 polymorphism on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites.
Karaźniewicz-Łada M; Danielak D; Rubiś B; Burchardt P; Komosa A; Lesiak M; Główka F
J Clin Pharm Ther; 2015 Apr; 40(2):226-31. PubMed ID: 25430046
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.
Wang XQ; Shen CL; Wang BN; Huang XH; Hu ZL; Li J
Gene; 2015 Mar; 558(2):200-7. PubMed ID: 25542807
[TBL] [Abstract][Full Text] [Related]
8. Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention.
Saiz-Rodríguez M; Belmonte C; Caniego JL; Koller D; Zubiaur P; Bárcena E; Romero-Palacián D; Eugene AR; Ochoa D; Abad-Santos F
Clin Ther; 2019 Jun; 41(6):1199-1212.e2. PubMed ID: 31128980
[TBL] [Abstract][Full Text] [Related]
9. The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.
Karaźniewicz-Łada M; Danielak D; Rubiś B; Burchardt P; Oszkinis G; Główka F
J Clin Pharmacol; 2014 Aug; 54(8):874-80. PubMed ID: 24782221
[TBL] [Abstract][Full Text] [Related]
10. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
Frelinger AL; Bhatt DL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Lampa M; Brooks JK; Barnard MR; Michelson AD
J Am Coll Cardiol; 2013 Feb; 61(8):872-9. PubMed ID: 23333143
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.
Giusti B; Gori AM; Marcucci R; Saracini C; Sestini I; Paniccia R; Valente S; Antoniucci D; Abbate R; Gensini GF
Pharmacogenet Genomics; 2007 Dec; 17(12):1057-64. PubMed ID: 18004210
[TBL] [Abstract][Full Text] [Related]
12. The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.
Saydam F; Değirmenci İ; Birdane A; Özdemir M; Ulus T; Özbayer C; Çolak E; Ata N; Güneş HV
Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):29-36. PubMed ID: 28135763
[TBL] [Abstract][Full Text] [Related]
13. Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
Braun OÖ; Angiolillo DJ; Ferreiro JL; Jakubowski JA; Winters KJ; Effron MB; Duvvuru S; Costigan TM; Sundseth S; Walker JR; Saucedo JF; Kleiman NS; Varenhorst C
Thromb Haemost; 2013 Dec; 110(6):1223-31. PubMed ID: 24009042
[TBL] [Abstract][Full Text] [Related]
14. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
[TBL] [Abstract][Full Text] [Related]
15. Impact of atorvastatin or rosuvastatin co-administration on platelet reactivity in patients treated with dual antiplatelet therapy.
Verdoia M; Nardin M; Sartori C; Pergolini P; Rolla R; Barbieri L; Marino P; Bellomo G; Suryapranata H; De Luca G;
Atherosclerosis; 2015 Dec; 243(2):389-94. PubMed ID: 26520891
[TBL] [Abstract][Full Text] [Related]
16. Determinants of high on-treatment platelet reactivity and agreement between VerifyNow and Multiplate assays.
Danielak D; Komosa A; Tomczak A; Graczyk-Szuster A; Lesiak M; Główka F; Karaźniewicz-Łada M
Scand J Clin Lab Invest; 2017 May; 77(3):190-198. PubMed ID: 28276728
[TBL] [Abstract][Full Text] [Related]
17. Impact of selected genetic factors on clopidogrel inactive metabolite level and antiplatelet response in patients after percutaneous coronary intervention.
Adamiak-Giera U; Czerkawska A; Olędzki S; Kurzawski M; Safranow K; Jastrzębska M; Gawrońska-Szklarz B
Pharmacol Rep; 2021 Apr; 73(2):583-593. PubMed ID: 33270185
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic effects of atorvastatin versus rosuvastatin in coronary artery disease patients with normal platelet reactivity while on dual antiplatelet therapy--the PEARL randomized cross-over study.
Pelliccia F; Rosano G; Marazzi G; Vitale C; Spoletini I; Franzoni F; Speziale G; Polacco M; Greco C; Gaudio C
Eur J Pharmacol; 2014 Feb; 725():18-22. PubMed ID: 24444439
[TBL] [Abstract][Full Text] [Related]
19. Clopidogrel utilization in patients with coronary artery disease and diabetes mellitus: should we determine CYP2C19*2 genotype?
Chouchene S; Dabboubi R; Raddaoui H; Abroug H; Ben Hamda K; Hadj Fredj S; Abderrazak F; Gaaloul M; Rezek M; Neffeti F; Hellara I; Sassi M; Khefacha L; Sriha A; Nouira S; Najjar MF; Maatouk F; Messaoud T; Hassine M
Eur J Clin Pharmacol; 2018 Dec; 74(12):1567-1574. PubMed ID: 30073432
[TBL] [Abstract][Full Text] [Related]
20. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.
Harmsze A; van Werkum JW; Bouman HJ; Ruven HJ; Breet NJ; Ten Berg JM; Hackeng CM; Tjoeng MM; Klungel OH; de Boer A; Deneer VH
Pharmacogenet Genomics; 2010 Jan; 20(1):18-25. PubMed ID: 19934793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
